Hubungan Kepatuhan Penggunaan Kelasi Besi Dengan Kadar Feritin Serum Pada Pasien Talasemia Anak Di RSUD Dr. Zainoel Abidin

Nadia Salsabila; Julinar Julinar; Silvia Yasmin Lubis

doi:10.31004/koloni.v5i3.1405

Authors

Nadia Salsabila Universitas Abulyatama
Julinar Julinar Universitas Abulyatama
Silvia Yasmin Lubis Universitas Abulyatama

DOI:

https://doi.org/10.31004/koloni.v5i3.1405

Keywords:

pediatric thalassemia, iron chelation therapy, adherence, serum ferritin

Abstract

Thalassemia is an inherited hemolytic disorder caused by impaired hemoglobin synthesis that requires lifelong regular blood transfusion therapy. Repeated blood transfusions can lead to iron accumulation, characterized by increased serum ferritin levels. Iron chelation therapy is required to reduce iron overload, with its effectiveness influenced by patient adherence. Objective: To analyze the relationship between adherence to iron chelation therapy and serum ferritin levels in pediatric patients with thalassemia at RSUD dr. Zainoel Abidin, Banda Aceh. Methods: This was an analytical observational study with a cross-sectional design using total sampling. The sample consisted of 137 patients who met the inclusion criteria. Adherence was measured using the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire, while serum ferritin levels were obtained from medical records. Data were analyzed using the Chi-Square test. Results: The majority of respondents were non-adherent to iron chelation therapy (64.2%) and had serum ferritin levels in the very high category (77.4%). All non-adherent respondents (88 patients) had serum ferritin levels in the very high category. The Chi-Square test demonstrated a statistically significant relationship between adherence to iron chelation therapy and serum ferritin levels (p = 0.000; p < 0.05). Conclusion: There was a statistically significant relationship between adherence to iron chelation therapy and serum ferritin levels in pediatric patients with thalassemia at RSUD dr. Zainoel Abidin, Banda Aceh.

References

Al-Awadhi, A., Alwehaidah, M., Al-sabaan, K., & Al-Ajmi, N. (2025). Assessment of ferritin and hepcidin levels in splenectomised and non-splenectomised β-thalassemia major patients and exploring a potential correlation with von Willebrand factor and ADAMTS-13. Annals of Hematology, 2229–2238.

Al Zabadi, H., Ieran, Z., & Taha, I. (2025). Assessment of Adherence to Iron Chelation Therapy Among Thalassemia Patients in Palestine. https://doi.org/10.1155/anem/6649477

Thalassaemia International Federation. (2021). Guidelines for the management of transfusion dependent thalassaemia (4th ed.). Nicosia, Cyprus: Thalassaemia International Federation.

Barua, T., Ali, G., & Arzu, M. (2021). Barriers to Adherence to Iron Chelation Therapy in Thalassemia Patients Semantic Schoolar.

Chawsamtong, S., Jetsrisuparb, A., Kengkla, K., & Jaisue, S. (2022). Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients. 20(1), 1–7. https://doi.org/doi.org/10.18549/PharmPract.2022.1.2570 Original

Chifman, J., Laubenbacher, R., & Torti, S. (2015). A Systems Biology Approach to Iron Metabolism. 201–225. https://doi.org/10.1007/978-1-4939-2095-2

Chong, C., Redzuan, A., Sathar, J., & Bakry, M. (2021). Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence.

Dr. Grentina, & DR. Dr. Pustika Amalia Wahidayat, S. A. (2016). Mengenal Thalasemia. IDAI.

Garcia-Casal, M., Pasricha, S., Martinez, R., Lopez-Perez, L., & Peña-Rosas, J. (2021). Serum or plasma ferritin concentration as an index of iron deficiency and overload (Review). Cochrane Database of Systematic Reviews, 5. https://doi.org/10.1002/14651858.CD011817.pub2.www.cochranelibrary.com

Gustiana, H., Gunantara, T., & Rathomi, H. S. (2020). Kepatuhan Konsumsi Obat Kelasi Besi dan Kadar Feritin Serum Pasien Talasemia Beta-Mayor di RSUD Al-Ihsan Bandung Drug Adherence of Iron-Chelating Agent and Serum Ferritin Levels of Beta- Major Thalassemia Patients in Al-Ihsan Hospital Bandung. 2(22), 26–30.

Hawa, T. D. S., Riza, M., & Kawuryan, D. L. (2023). Hubungan Tingkat Kepatuhan Konsumsi Obat Kelasi Besi Dengan Kadar Ferritin Pada Pasien Thalassemia Anak Di Rsud Dr. Moewardi. Infokes: Jurnal Ilmiah Rekam Medis Dan Informatika Kesehatan, 13(1), 46–51. https://doi.org/10.47701/infokes.v13i1.2533

Kamperidis, V., Vlachou, M., Pappa, Z., Pantelidou, D., Karamitsos, T., Papadopoulou, D., Kartas, A., Boutou, A., Ventoulis, I., Vlachaki, E., Giannakoulas, G., & Karvounis, H. (2021). Prediction of longterm survival in patients with transfusion dependent hemoglobinopathies Insights from cardiac imaging and ferritin. 62, 429–438.

Mehmood, R., Yaqoob, U., Sarfaraz, A., & Zubair, U. (2018). Complete blood picture with skeletal and visceral changes in patients with thalassemia major. International Journal of Health Sciences (Qassim), 12(4), 3–10.

Mohamed, R., Abdul Rahman, A. H., Masra, F., & Abdul Latiff, Z. (2022). Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia. Frontiers in Pediatrics, 10, 951947. doi:10.3389/fped.2022.951947

Permatasari, T. D., Kartikasari, G. D., & Ismail, C. (2023). Correlation between adherence therapy of iron chelation levels with serum ferritin levels in major beta-thalassemia patients at Kediri District General Hospital. Indonesian Health Journal, 2(2), 38–43. doi:10.58344/ihj.v2i2.68

Reddy, P. S., Locke, M., & Badawy, S. M. (2022). A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia. Annals of Medicine, 54(1), 326–342. doi:10.1080/07853890.2022.2028894

Kementerian Kesehatan Republik Indonesia. (2018). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1/2018 tentang Pedoman Pelayanan Kedokteran Tata Laksana Thalasemia. Jakarta, Indonesia: Kementerian Kesehatan Republik Indonesia.

Rejeki, D. S. S., Nurhayati, N., Supriyanto, S., & Kartikasari, E. (2012). Studi epidemiologi deskriptif talasemia. Kesmas: Jurnal Kesehatan Masyarakat Nasional, 7(3), 139–144. doi:10.21109/kesmas.v7i3.61

World Health Organization. (1989). Report of the fifth WHO working group on the feasibility study on hereditary disease community control programmes (hereditary anaemias): Cagliari, Sardinia. Geneva, Switzerland: Author.

Rhodes, C. E., Denault, D., & Varacallo, M. A. (2022). Physiology, Oxygen Transport. StatPearls Publishing LLC.

Rujito, L. (2019). Talasemia: Genetik dasar dan pengelolaan terkini. Purwokerto, Indonesia: Universitas Jenderal Soedirman Press.

Rumah Sakit Umum Daerah dr. Zainoel Abidin, I. R. M. (2025). Data rekam medis pasien talasemia yang datang berkunjung ke Rumah Sakit Umum Daerah dr. Zainoel Abidin Banda Aceh periode Januari–Desember 2025. Unpublished Raw Data.

Sabaté, E. (Ed.). (2003). Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: World Health Organization.

Triwardhani, E. R., Reniarti, L., & Setiabudiawan, B. (2022). Hubungan jenis dan tingkat kepatuhan pengobatan kelasi besi oral dengan kadar feritin serum pada penyandang talasemia beta mayor anak. Sari Pediatri, 24(1), 23–30. doi:10.14238/sp24.1.2022.23-30

World Health Organization. (2006). Thalassaemia and other haemoglobinopathies. Geneva, Switzerland: Author.